Sanofi - Aventis Groupe: Press Release: Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIOTM to redefine expectations for treatment of children <12 years of age with hemophilia A
Completed XTEND-Kids Phase 3 study strengthens potential of ALTUVIIIO to redefine expectations for treatment of children ophilia A Paris, March 2, 2023. The XTEND-Kids phase